Teresa C. Riga

Teresa C. Riga

Auto-generated profile, based on publicly available information

Teresa C. Riga

Columbia University Medical Center, 622 W. 168th St., New York, NY 10032, United States

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2016 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
KHKathleen T. Hickey
Kathleen T. Hickey
NHNicole R. Hauser
Nicole R. Hauser
LVLaura E. Valente
Laura E. Valente
TRTeresa C. Riga
Teresa C. Riga
AFAshton P. Frulla
Ashton P. Frulla
DWDaniel Y. Wang
Daniel Y. Wang
Atrial fibrillation is a major public health problem and is the most common cardiac arrhythmia, affecting an estimated 2.7 million Americans. The true prevalence of atrial fibrillation is likely underestimated because episodes are often sporadic; therefore, it is challenging to detect and record an occurrence in a “real world” setting. To date, mobile health tools that promote earlier detection and treatment of atrial fibrillation and improvement in self-management behaviors and knowledge have not been evaluated. This study will be the first to address the epidemic problem of atrial fibrillation with a novel approach utilizing advancements in mobile health electrocardiogram technology to empower patients to actively engage in their healthcare and to evaluate impact on quality of life and quality-adjusted life years. Furthermore, sending a daily electrocardiogram transmission, coupled with receiving educational and motivational text messages aimed at promoting self-management and a healthy lifestyle may improve the management of chronic cardiovascular conditions (e.g., hypertension, diabetes, heart failure, etc.). Therefore, we are currently conducting a randomized controlled trial to assess the efficacy of a mobile health intervention, iPhone® Helping Evaluate Atrial fibrillation Rhythm through Technology (iHEART) versus usual cardiac care. The iHEART study is a single center, prospective, randomized controlled trial. A total of 300 participants with a recent history of atrial fibrillation will be enrolled. Participants will be randomized 1:1 to receive the iHEART intervention, receiving an iPhone® equipped with an AliveCor® Mobile ECG and accompanying Kardia application and behavioral altering motivational text messages or usual cardiac care for 6 months. This will be the first study to investigate the utility of a mobile health intervention in a “real world” setting. We will evaluate the ability of the iHEART intervention to improve the detection and treatment of recurrent atrial fibrillation and assess the intervention's impact on improving clinical outcomes, quality of life, quality-adjusted life-years and disease-specific knowledge. NCT02731326 ; Verified April 2016

1 April 2018 in Nurse Education Today
Verified
Journal Article
Closed access
KHKathleen T. Hickey
Kathleen T. Hickey
JTJacquelyn Y. Taylor
Jacquelyn Y. Taylor
TBTaura L. Barr
Taura L. Barr
NHNicole R. Hauser
Nicole R. Hauser
HJHaomiao Jia
Haomiao Jia
Maria KatapodiMaria Katapodi
Maria Katapodi

24 August 2017 in The Journal for Nurse Practitioners
Verified
Journal Article
Closed access
PDF file
KHKathleen T. Hickey
Kathleen T. Hickey
TRTeresa C. Riga
Teresa C. Riga
SMShazia Mitha
Shazia Mitha
MRMeghan Reading
Meghan Reading
KWKate N. Warren
Kate N. Warren
MBMary W. Byrne
Mary W. Byrne